2-[5-(benzyloxy)-1H-indol-1-yl]ethanol | 374818-89-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 2-[5-(benzyloxy)-1H-indol-1-yl]ethanol
• 英文别名: N-(2-hydroxyethyl)-5-benzyloxyindole；2-(5-benzyloxy-indol-1-yl)ethanol；2-(5-phenylmethoxyindol-1-yl)ethanol
• CAS: 374818-89-0
• 化学式: C₁₇H₁₇NO₂
• 分子量: 267.327
• InChiKey: JXYUCVZLJRVUJL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  20
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  34.4
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-[5-(benzyloxy)-1H-indol-1-yl]ethanol 在 4-二甲氨基吡啶 、 乙酸酐 、 三乙胺 作用下， 以 四氢呋喃 为溶剂， 以99%的产率得到N-(2-acetoxyethyl)-5-benzyloxyindole
  参考文献：
  名称：

  Neuroprotective and anti-proliferative compounds

  摘要：

  这项发明涉及环取代吡咯β-咔啉衍生物和3-(1H-吲哚-3-基)-1H-吡咯-2,5-二酮的环取代和结构衍生物，其作为神经保护和抗增殖化合物具有用途。还公开了这些化合物的制备方法，选择的生物学特性以及这些化合物在治疗人类神经系统的各种神经退行性和炎症性疾病以及治疗其他各种增殖性疾病中的用途，这些疾病的特征是失去生长或细胞分化控制，包括但不限于癌症和炎症。

  公开号：

  US20040102467A1
• 作为产物：
  描述：

  碳酸乙烯酯 、 5-苄氧基吲哚 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 0.5h， 以69%的产率得到2-[5-(benzyloxy)-1H-indol-1-yl]ethanol
  参考文献：
  名称：

  潜在的双重芳香化酶-类固醇硫酸酯酶抑制剂2-溴--4-{[（4-氰基苯基）（4H-1,1,2,4-三唑-4-基）氨基]甲基}苯基氨基磺酸的双环衍生物：合成，SAR，晶体结构，体外和体内活性

  摘要：

  基于芳香酶抑制剂（AI）4-[（4-溴苄基）（4 H -1,2,4-三唑-4-基）的一系列包含双芳香酶-硫酸酯酶抑制剂（DASI）的双环的设计与合成报道了）氨基]苄腈。JEG-3细胞的生物学评估揭示了结构与活性之间的关系。确定了氨基磺酸盐23的X射线晶体结构，并将选定的化合物对接成芳香酶和甾族硫酸酯酶（STS）的晶体结构。在含氨基磺酸盐的系列中，含有萘环的化合物既是最有效的AI（39，IC 50 AROM = 0.25 n M）又是最好的STS抑制剂（31，IC 50 STS = 26 n M）。最有前途的DASI是39（IC 50 AROM = 0.25 n M，IC 50 STS = 205 n M），口服10 mg kg -1口服评估，显示出对芳香酶（93％）和STS的有效抑制作用（ 3小时后93％）。因此，含有双环系统的DASI可以达到有效的芳香化酶和STS抑制的目的。这种DASI

  DOI：

  10.1002/cmdc.201000203

文献信息

• [EN] USE OF alpha-PHENYLTHIOCARBOXYLIC AND alpha-PHENYLOXYCARBOXYLIC ACIDS WITH SERUM-GLUCOSE-LOWERING AND SERUM-LIPID-LOWERING ACTIVITY<br/>[FR] UTILISATION D'ACIDES 20040708WO03059875A2SIGMA TAU IND FARMACEUTI [IT], et al200307241,74-7,14,17,18,20-26PX1-7,10,15PXWINEGAR D A ET AL: "Role of peroxisome proliferator-activated receptors in atherosclerosis", CURRENT OPINION IN CARDIOVASCULAR, PULMONARY AND RENAL INVESTIGATIONAL DRUGS 2000 UNITED KINGDOM, vol. 2, no. 3, 2000, pages 233 - 243, XP008029337, ISSN: 1464-8482WINEGAR D A ET ALRole of peroxisome proliferator-activated receptors in atherosclerosisCURRENT OPINION IN CARDIOVASCULAR, PULMONARY AND RENAL INVESTIGATIONAL DRUGS 2000 UNITED KINGDOM2000231464-8482233243page 236, left-hand column, last paragraph237L1,2<table>1</table>X1,2,7,8,10-12,15XBROOKS D A ET AL: "Design and synthesis of 2-methyl-2-{4-[2-(5-methyl-2- aryloxazol-4-yl)ethoxy]phenoxy}propionic acids: a new class of dual PPARalpha/gamma agonists", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 44, no. 13, 21 June 2001 (2001-06-21), pages 2061 - 2064, XP002184099, ISSN: 0022-2623BROOKS D A ET ALDesign and synthesis of 2-methyl-2-{4-[2-(5-methyl-2- aryloxazol-4-yl)ethoxy]phenoxy}propionic acids: a new class of dual PPARalpha/gamma agonistsJOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US2001062144130022-262320612064Chart 1<table>1</table>2063R1,2X1-3,7,10-12,15XLALEZARI I ET AL: "LR-16 A COMPOUND WITH POTENT EFFECTS ON THE OXYGEN AFFINITY OF HEMOGLOBIN ON BLOOD CHOLESTEROL AND ON LOW DENSITY LIPOPROTEIN", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 85, no. 16, 1988, 1988, pages 6117 - 6121, XP001161155, ISSN: 0027-8424LALEZARI I ET ALLR-16 A COMPOUND WITH POTENT EFFECTS ON THE OXYGEN AFFINITY OF HEMOGLOBIN ON BLOOD CHOLESTEROL AND ON LOW DENSITY LIPOPROTEINPROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES1988198885160027-842461176121Scheme 1page 6117, abstractX1,2,10-12,15XUS3262850AMOSS JONES WILLIAM GLYNNE, et al19660726111719X1,2,10-12,15XGB1422679AFUNAI PHARMACEUTICAL IND LTD19760128112126X1,2,7,10-12,15XGRONOWITZ S ET AL: "POTENTIAL HYPOLIPIDEMIC AGENTS XIX. SYNTHESIS AND LIPID-LOWERING PROPERTIES OF THIOPHENE DERIVATIVES RELATED TO CLOFIBRATE", ACTA PHARMACEUTICA SUECICA, XX, XX, vol. 15, no. 5, 1978, pages 361 - 367, XP001053343, ISSN: 0001-6675GRONOWITZ S ET ALPOTENTIAL HYPOLIPIDEMIC AGENTS XIX. SYNTHESIS AND LIPID-LOWERING PROPERTIES OF THIOPHENE DERIVATIVES RELATED TO CLOFIBRATEACTA PHARMACEUTICA SUECICA, XX, XX19781550001-6675361367<table>1</table>3641X1,3,10-12,15XDURIEZ P ET AL: "POST-STATIN APPROACHES TO HYPERLIPIDAEMIA", EXPERT OPINION ON INVESTIGATIONAL DRUGS, ASHLEY PUBLICATIONS LTD., LONDON, GB, vol. 7, no. 12, December 1998 (1998-12-01), pages 1997 - 2009, XP000892408, ISSN: 1354-3784DURIEZ P ET ALPOST-STATIN APPROACHES TO HYPERLIPIDAEMIAEXPERT OPINION ON INVESTIGATIONAL DRUGS, ASHLEY PUBLICATIONS LTD., LONDON, GB1998127121354-37841997200920023.1Y1-15YBROWN P J ET AL: "A Ureido-Thiobutyric Acid (GW9578) is a subtype-Selective PPARalpha Agonist with Potent lipid-Lowering Activity", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 42, no. 19, 9 April 1999 (1999-04-09), pages 3785 - 3788, XP002128791, ISSN: 0022-2623BROWN P J ET ALA Ureido-Thiobutyric Acid (GW9578) is a subtype-Selective PPARalpha Agonist with Potent lipid-Lowering ActivityJOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US1999040942190022-262337853788Chart 1page 3787, left-hand column, last paragraphY1-15YGUERRE-MILLO MICHELE ET AL: "Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 275, no. 22, 2 June 2000 (2000-06-02), pages 16638 - 16642, XP002275720, ISSN: 0021-9258GUERRE-MILLO MICHELE ET ALPeroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposityJOURNAL OF BIOLOGICAL CHEMISTRY20000602275220021-9258166381664216641R3Y1-15YZHANG BEI B ET AL: "New approaches in the treatment of type 2 diabetes", CURRENT OPINION IN CHEMICAL BIOLOGY, vol. 4, no. 4, August 2000 (2000-08-01), pages 461 - 467, XP002275721, ISSN: 1367-5931ZHANG BEI B ET ALNew approaches in the treatment of type 2 diabetesCURRENT OPINION IN CHEMICAL BIOLOGY200008441367-5931461467463L31Y1-15YHAWKE ROY L ET AL: "Potent hypocholesterolemic activity of novel ureido phenoxyisobutyrates correlates with their intrinsic fibrate potency and not with their ACAT inhibitory activity", JOURNAL OF LIPID RESEARCH, vol. 38, no. 6, 1997, pages 1189 - 1203, XP002275722, ISSN: 0022-2275HAWKE ROY L ET ALPotent hypocholesterolemic activity of novel ureido phenoxyisobutyrates correlates with their intrinsic fibrate potency and not with their ACAT inhibitory activityJOURNAL OF LIPID RESEARCH19973860022-227511891203entire documentAA
  申请人：SIGMA TAU IND FARMACEUTI

  公开号：WO2004056355A1

  公开（公告）日：2004-07-08

  The use is described of derivatives of α-phenylthiocarboxylic and α-phenyloxycarboxylic acids with formula (I): in which the substituents have the meanings described in the text, for the preparation of a medicine for the prophylaxis and treatment of diabetes, particularly type 2 diabetes, its complications, the various forms of insulin resistance, and hyperlipidaemias.

  本文描述了使用具有以下公式（I）的α-苯基硫代羧酸和α-苯基氧羧酸的衍生物进行制备药物，用于预防和治疗糖尿病，特别是2型糖尿病、其并发症、各种形式的胰岛素抵抗和高脂血症。其中，取代基的含义在文本中有描述。
• Use of alpha-phenylthiocarboxylic and alpha-phenyloxycarboxylic acids with serum-glucose-lowering and serum-lipid-lowering activity
  申请人：Giannessi Fabio

  公开号：US20060154979A1

  公开（公告）日：2006-07-13

  The use is described of derivatives of α-phenylthiocarboxylic and α-phenyloxycarboxylic acids with formula (i): in which the substituents have the meanings described in the text, for the preparation of a medicine for the prophylaxis and treatment of diabetes, particularly type 2 diabetes, its complications, the various forms of insulin resistance, and hyperlipidaemias.

  使用α-苯基硫代羧酸和α-苯氧羧酸的衍生物(i)来制备一种药物，用于预防和治疗糖尿病，尤其是2型糖尿病，其并发症，各种形式的胰岛素抵抗和高脂血症。其中，取代基的含义如文本所述。
• Derivatives of alpha-phenylthiocarboxylic and alpha-phenyloxy-carboxylic acids useful for the treatment of diseases responding to PPARalpha activation
  申请人：Giannessi Fabio

  公开号：US20080027098A1

  公开（公告）日：2008-01-31

  Formula (I) compounds are described in which the substituents have the meanings described in the text, and which are useful for the treatment of diseases responding to PPARαactivation, such as heart failure, the hyperlipaemias and atherosclerosis.

  本文中描述了具有文本中所述含义的取代基的公式(I)化合物，这些化合物对于治疗对PPARα激活有反应的疾病，如心力衰竭，高脂血症和动脉粥样硬化是有用的。
• NEUROPROTECTIVE AND ANTI-PROLIFERATIVE COMPOUNDS
  申请人：Aegera Therapeutics Inc.

  公开号：EP1283836A2

  公开（公告）日：2003-02-19
• USE OF ALPHA-PHENYLTHIOCARBOXYLIC ACIDS WITH SERUM-GLUCOSE-LOWERING AND SERUM-LIPID-LOWERING ACTIVITY
  申请人：SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A.

  公开号：EP1572180B1

  公开（公告）日：2009-02-25